CCO Management Series
Treatment Strategies With NNRTIs: Use in First-Line vs Later Regimens
Characteristics of Optimal First-Line Regimens
|
Module 1 of 3
|
Program Director:
John P. Phair, MD
|
|
 Topics covered include:
- Introduction
- Options for First-Line Antiretroviral Therapy
- Dosing Considerations
- Short-term Tolerability
- Clinical Management Requirements
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the optimal characteristics of first-line antiretroviral regimens. Review the similarities and differences between the NRTI backbones recommended as preferred options by the DHHS. Compare and contrast the characteristics of efavirenz- and lopinavir/ritonavir-based initial regimens.
|
Antiretroviral Therapy with NNRTIs: What's the Evidence?
|
Module 2 of 3
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- NNRTI Initial Therapy
- Studies of Efavirenz in Initial Therapy
- Studies of Efavirenz in Initial Therapy (Cont.)
- Studies of Efavirenz in Initial Therapy (Cont.)
Learning Objectives
Upon completion of this activity, participants should be able to:
Review data from comparative studies that included the use of an NNRTI-based regimen in initial therapy. Describe findings from studies in which NNRTI-based regimens were evaluated as second-line therapy. Discuss consideration regarding the use of NNRTI-based regimens later than second-line therapy.
|
Strategic Considerations in the Use of NNRTIs
|
Module 3 of 3
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Positioning of NNRTIs in Antiretroviral Treatment Regimens
- Positioning of NNRTIs in Antiretroviral Treatment Regimens (Cont.)
- Positioning of NNRTIs in Antiretroviral Treatment Regimens (Cont.)
- Positioning of NNRTIs in Antiretroviral Treatment Regimens (Cont.)
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss principles that should be observed to ensure maximal benefit from NNRTIs, including consideration regarding adherence and impact on future options. Review clinical strategies for the use of NNRTIs, including first-line therapy, use in later regimens, and switch strategies. Describe individual patient characteristics that may affect the decision whether to use NNRTIs, including disease stage, comorbidities, interactions, and special populations.
|
Interactive Case Challenges
Management of a Patient Initiating a First-Line NNRTI-Based HAART Regimen
Program Director:
John P. Phair, MD
|
|
 Test your ability to manage adverse effects in a patient initiating therapy, and compare your decisions with those of other readers and our expert faculty. Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the incidence and management of CNS side effects associated with efavirenz. Describe the incidence and management of hepatotoxicity with nevirapine. Review factors that should be weighed when considering a structured treatment interruption.
|
Management of a Patient With Early Virologic Failure of an Initial PI-Based HAART Regimen
Program Director:
John P. Phair, MD
|
|
Consider treatment options and the potential role of NNRTIs in the clinical management of a patient experiencing virologic failure on a first-line protease inhibitor-based regimen. Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss considerations regarding whether to use an NNRTI in a treatment-experienced, NNRTI-naive patient. Review the evaluation and management of jaundice in HIV-infected patients. Describe drug-drug interactions between NNRTIs and lipid-lowering agents.
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by University of Alabama School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|